相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Altamira Therapeutics introduced GenePhore™, a new DNA delivery adaptation of its xPhore™ platform, demonstrating efficient cell transfection and protein expression for applications including DNA vaccines and gene editing. - The company's associate Altamira Medica AG achieved regulatory milestones with Bentrio® nasal spray, receiving EU MDR clearance and Chinese NMPA approval for allergic rhinitis treatment. - Altamira reduced its operating loss from $6.9 million in 2024 to $4.4 million in 2025 while advancing preparations for spinning off its nucleic acid delivery business. - The company raised $0.7 million through convertible loans for its Swiss subsidiary and plans an equity funding round in 2026 to support growth of the nucleic acid delivery platform.
- Altamira Therapeutics' Bentrio nasal spray received marketing approval from China's NMPA for allergic rhinitis treatment, targeting nearly 200 million affected Chinese patients. - The drug-free, preservative-free nasal spray demonstrated statistically significant efficacy in clinical trials, with a p-value of 0.013 for symptom reduction compared to saline. - Nuance Pharma will launch and distribute Bentrio in Mainland China, marking a major milestone for the company's international growth strategy. - The product also recently obtained EU Medical Device Regulation certification, facilitating regulatory approval in various other countries beyond China.
- Altamira Therapeutics successfully demonstrated DNA delivery capabilities using its xPhore nanoparticle platform, showing efficient cellular transfection and protein expression in vitro experiments. - The company will commercialize this DNA delivery technology as GenePhore, complementing its existing RNA delivery platforms for siRNA, mRNA, and circular RNA applications. - GenePhore targets the rapidly expanding gene delivery market, valued at $5.35 billion in 2024 and projected to exceed $22.8 billion by 2034. - The peptide-based nanoparticle technology addresses key challenges in DNA delivery for applications including DNA vaccines, gene editing, and protein replacement therapies.
- Altamira Therapeutics completed a strategic spin-off of its RNA delivery subsidiary ATAG to private equity investors, reducing operating losses by 32.9% and net losses by 64.6% in the first half of 2025. - The company's xPhore platform has expanded to include CycloPhore for circular RNA delivery, offering enhanced stability and protein expression compared to linear mRNA for oncology and autoimmune applications. - Altamira secured four collaborations focused on RNA delivery in 2025, including partnerships for circular RNA and radiopharmaceutical applications, positioning the company to capture market share in the projected $10 billion RNA delivery market by 2030. - Despite operational improvements, the company faces critical liquidity constraints with cash reserves of only $4,000 as of June 2025, making the success of partnerships and licensing deals essential for sustainability.
- Altamira Therapeutics has entered into a collaboration agreement with an undisclosed company to evaluate its CycloPhore platform for delivering circular RNA payloads. - The partnership will test CycloPhore nanoparticles in vitro and in vivo, with the partner having an option to negotiate licensing rights for commercialization. - CycloPhore represents a novel approach to RNA delivery that enables targeting of extrahepatic tissues and could allow for lower dosing and less frequent administrations compared to linear mRNA. - The collaboration marks the first partnership for Altamira's recently launched CycloPhore platform, which is based on the company's proprietary xPhore technology featuring a patented 21-amino acid peptide.
- Altamira Therapeutics has entered into a collaboration agreement with an undisclosed radiopharmaceutical company to evaluate the use of its proprietary RNA delivery platform for enhanced cancer targeting. - The partnership will test Altamira's RNA nanoparticles in combination with the partner's radiopharmaceuticals through in vitro and in vivo studies. - Upon successful completion of experiments, the collaboration partner will have the option to negotiate licensing and supply agreements for commercializing the combined therapy approach. - The global radiopharmaceutical market reached $8.4 billion in 2024 and is projected to grow to $17.1 billion by 2033, representing significant commercial potential.
